US equities
|
MU
$1,039.21
▼-4.48%
NVDA
$230.24
▼-3.04%
SNDK
$1,608.15
▼-4.98%
AMD
$617.91
▼-4.33%
INTC
$106.05
▼-6.25%
SPCX
$161.78
▼-3.47%
META
$715.96
▼-0.74%
PLTR
$196.06
▲+1.00%
MU
$1,039.21
▼-4.48%
NVDA
$230.24
▼-3.04%
SNDK
$1,608.15
▼-4.98%
AMD
$617.91
▼-4.33%
INTC
$106.05
▼-6.25%
SPCX
$161.78
▼-3.47%
META
$715.96
▼-0.74%
PLTR
$196.06
▲+1.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
17.91
+0.41 (+2.34%)
Delayed Quote
Updated: 1:57 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
36
37
Next >
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
June 26, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 26, 2025
From
The Schall Law Firm
Via
Business Wire
SRPT SECURITIES NOTICE: Sarepta Therapeutics, Inc. Investors May Have Been Affected by Fraud - Contact BFA Law if You Suffered Losses
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 26, 2025
Via
ACCESS Newswire
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
↗
June 25, 2025
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.
Via
Benzinga
Topics
Death
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
↗
June 25, 2025
Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys.
Via
Investor's Business Daily
Topics
Death
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
↗
June 25, 2025
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.
Via
Stocktwits
Topics
Artificial Intelligence
Death
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
↗
June 25, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 25, 2025
Via
ACCESS Newswire
Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts
↗
June 25, 2025
Via
Benzinga
BFA Law Notifies Sarepta Therapeutics, Inc. (SRPT) Investors that the Company is being Investigated for Securities Fraud - Contact the Firm if You Lost Money
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SRPT FRAUD NOTIFICATION: Did Sarepta Therapeutics, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law
June 23, 2025
Via
ACCESS Newswire
SRPT REVIEW: Sarepta Therapeutics, Inc. is Being Investigated for Securities Fraud After Elevidys Death - Investors Are Urged to Contact BFA Law
June 20, 2025
Via
ACCESS Newswire
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
↗
June 20, 2025
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Via
Benzinga
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
↗
June 20, 2025
Via
Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
↗
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Via
Investor's Business Daily
Topics
Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 20, 2025
Via
ACCESS Newswire
2 Growth Stocks with All-Star Potential and 1 to Ignore
June 20, 2025
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...
Via
StockStory
Topics
Artificial Intelligence
SRPT INQUIRY NOTICE: Lose Money on Sarepta Therapeutics, Inc.? Contact BFA Law About its Securities Fraud Investigation
June 19, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
June 18, 2025
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
Via
MarketBeat
Topics
Earnings
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
June 17, 2025
Via
TheNewswire.com
Topics
Fraud
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
June 17, 2025
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
↗
June 17, 2025
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.
Via
Benzinga
Topics
Government
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN)
↗
June 17, 2025
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.
Via
Chartmill
Topics
Economy
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
↗
June 17, 2025
Via
Benzinga
Topics
Stocks
1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of
June 17, 2025
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...
Via
StockStory
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
36
37
Next >
